Celgene Corporation (CELG) EPS Estimated At $1.62

July 18, 2017 - By test

 Celgene Corporation (CELG) EPS Estimated At $1.62
Investors sentiment decreased to 0.98 in Q4 2016. Its down 0.13, from 1.11 in 2016Q3. It worsened, as 57 investors sold Celgene Corporation shares while 470 reduced holdings. 116 funds opened positions while 398 raised stakes. 587.86 million shares or 1.69% more from 578.10 million shares in 2016Q3 were reported.
Middleton & Inc Ma reported 0.05% in Celgene Corporation (NASDAQ:CELG). Mckinley Ltd Liability Delaware has invested 0.2% in Celgene Corporation (NASDAQ:CELG). Virginia Retirement Et Al has invested 0.35% in Celgene Corporation (NASDAQ:CELG). Silvercrest Asset Mngmt Group Incorporated Lc holds 44,100 shares or 0.06% of its portfolio. Colony Ltd Co reported 0.04% in Celgene Corporation (NASDAQ:CELG). Clear Harbor Asset Llc has 0.43% invested in Celgene Corporation (NASDAQ:CELG) for 17,703 shares. Hl Fincl Svcs Limited Liability reported 4,622 shares stake. 5,150 were accumulated by Spc Fincl. Hudock Cap Group Inc, a Pennsylvania-based fund reported 100 shares. Prudential Inc has 0.51% invested in Celgene Corporation (NASDAQ:CELG). Alphamark Advsrs Lc accumulated 26 shares. Biondo Investment Limited Liability Company invested 5.44% of its portfolio in Celgene Corporation (NASDAQ:CELG). Hudson Canyon Counselors Lc stated it has 7,286 shares or 1.22% of all its holdings. Endurant Cap Mngmt Ltd Partnership stated it has 1.7% of its portfolio in Celgene Corporation (NASDAQ:CELG). Tci Wealth Advisors stated it has 4,198 shares.

Since February 27, 2017, it had 0 buys, and 6 selling transactions for $5.51 million activity. CASEY MICHAEL D sold $1.16M worth of stock or 9,250 shares. The insider VESSEY RUPERT sold $497,672. The insider KAPLAN GILLA sold 14,033 shares worth $1.74 million.

Investors wait Celgene Corporation (NASDAQ:CELG) to report on July, 27. its quarterly earnings Wall Street analysts expect $1.62 EPS, up $0.34 or 26.56 % from last year’s $1.28 same quarter earnings. This translates into $1.27 billion profit for CELG giving the stock a 20.81 P/E. This is assuming the current $1.62 EPS is accurate. Celgene Corporation’s Wall Street analysts see 5.88 % EPS growth, taking into account the $1.53 EPS reproted in the previous quarter, The stock increased 0.22% or $0.3 during the last trading session, reaching $134.87. About 2.78M shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since July 18, 2016 and is uptrending. It has outperformed by 0.30% the S&P500.

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 23 analysts covering Celgene Corporation (NASDAQ:CELG), 18 have Buy rating, 0 Sell and 5 Hold. Therefore 78% are positive. Celgene Corporation had 53 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Friday, June 30 by BTIG Research. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Wednesday, September 9 by Jefferies. Raymond James initiated the shares of CELG in report on Tuesday, September 1 with “Strong-Buy” rating. The stock of Celgene Corporation (NASDAQ:CELG) has “Overweight” rating given on Thursday, October 1 by JP Morgan. Cowen & Co maintained the shares of CELG in report on Wednesday, August 12 with “Outperform” rating. Cantor Fitzgerald maintained Celgene Corporation (NASDAQ:CELG) on Friday, July 24 with “Buy” rating. The firm has “Buy” rating given on Friday, November 6 by Canaccord Genuity. The firm earned “Hold” rating on Wednesday, November 9 by Standpoint Research. The rating was initiated by Suntrust Robinson with “Buy” on Thursday, January 7. On Thursday, January 14 the stock rating was initiated by Standpoint Research with “Buy”.

Celgene Corporation is an integrated global biopharmaceutical company. The company has market cap of $105.39 billion. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. It has a 50.8 P/E ratio. The Company’s commercial-stage products include REVLIMID , POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide).

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Fool.com which released: “Better Buy: Biogen Inc. vs. Celgene Corporation” on July 16, 2017, also Reuters.com with their article: “Celgene signs deal with BeiGene for tumor cancer treatment” published on July 06, 2017, Seekingalpha.com published: “Celgene: I Don’t Necessarily Understand The Science, But I Love The Numbers” on June 22, 2017. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Fool.com and their article: “Better Buy: Amgen Inc. vs. Celgene Corporation” published on July 08, 2017 as well as Investorplace.com‘s news article titled: “Dipping Celgene Corporation (CELG) Stock Is Begging to Be Bought” with publication date: June 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.